SG10201810634UA - Controlling the formation of disulfide bonds in protein solutions by adding reducing agents - Google Patents
Controlling the formation of disulfide bonds in protein solutions by adding reducing agentsInfo
- Publication number
- SG10201810634UA SG10201810634UA SG10201810634UA SG10201810634UA SG10201810634UA SG 10201810634U A SG10201810634U A SG 10201810634UA SG 10201810634U A SG10201810634U A SG 10201810634UA SG 10201810634U A SG10201810634U A SG 10201810634UA SG 10201810634U A SG10201810634U A SG 10201810634UA
- Authority
- SG
- Singapore
- Prior art keywords
- formation
- disulfide bonds
- controlling
- protein solutions
- reducing agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
CONTROLLING THE FORMATION OF DISULFIDE BONDS IN PROTEIN SOLUTIONS BY ADDING REDUCING AGENT S Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also 5 disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution. [No Figure] 10
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004175P | 2014-05-28 | 2014-05-28 | |
| US14/668,820 US10647777B2 (en) | 2014-05-28 | 2015-03-25 | Methods of controlling the formation of disulfide bonds in protein solutions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201810634UA true SG10201810634UA (en) | 2018-12-28 |
Family
ID=53396587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609480UA SG11201609480UA (en) | 2014-05-28 | 2015-05-28 | Controlling the formation of disulfide bonds in protein solutions by adding reducing agents |
| SG10201810634UA SG10201810634UA (en) | 2014-05-28 | 2015-05-28 | Controlling the formation of disulfide bonds in protein solutions by adding reducing agents |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201609480UA SG11201609480UA (en) | 2014-05-28 | 2015-05-28 | Controlling the formation of disulfide bonds in protein solutions by adding reducing agents |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10647777B2 (en) |
| EP (1) | EP3149033B1 (en) |
| JP (2) | JP6742919B2 (en) |
| KR (1) | KR102457995B1 (en) |
| CN (1) | CN107001407B (en) |
| AU (1) | AU2015266860B2 (en) |
| CA (1) | CA2950190C (en) |
| IL (1) | IL249142B (en) |
| MX (1) | MX2016015615A (en) |
| RU (2) | RU2020115514A (en) |
| SG (2) | SG11201609480UA (en) |
| TW (2) | TWI736071B (en) |
| WO (1) | WO2015184183A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017196810A1 (en) * | 2016-05-10 | 2017-11-16 | Medimmune, Llc | Prevention of protein disulfide bond reduction |
| MX2019015304A (en) * | 2017-06-21 | 2020-02-17 | Cephalon Inc | Cation exchange chromatography wash buffer. |
| TWI825066B (en) * | 2018-02-01 | 2023-12-11 | 美商再生元醫藥公司 | Quantitation and modeling of quality attributes of therapeutic monoclonal antibodies |
| US20220135705A1 (en) * | 2019-03-26 | 2022-05-05 | Kaneka Corporation | Method for supporting thiol group-including compound |
| KR102370142B1 (en) * | 2020-03-23 | 2022-03-04 | 프레스티지바이오로직스 주식회사 | Hybrid System of Culture and Purification Process for the Production of Antibody Pharmaceuticals |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4470925A (en) | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
| TW517059B (en) * | 1994-07-25 | 2003-01-11 | Ciba Geigy Ag | New process for the production of biologically active protein |
| ATE315410T1 (en) * | 1998-11-03 | 2006-02-15 | Centocor Inc | MODIFIED ANTIBODIES AND ANTIBODY FRAGMENTS WITH EXTENDED DURATION OF ACTIVITY |
| KR101370253B1 (en) * | 2004-10-22 | 2014-03-05 | 암젠 인크 | Methods for refolding of recombinant antibodies |
| CA2681974C (en) * | 2007-03-29 | 2019-12-31 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| US20090053786A1 (en) * | 2007-07-09 | 2009-02-26 | Yung-Hsiang Kao | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| US20110086366A1 (en) | 2008-02-22 | 2011-04-14 | Genmab A/S | Methods for assessing the risk of adverse events upon treatment with igg4 antibodies |
| JP6040148B2 (en) * | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | Heterodimeric antibody Fc-containing protein and production method thereof |
| CN102008732B (en) | 2010-11-08 | 2012-10-24 | 武汉华耀生物医药有限公司 | Folate conjugated antibody medicament and preparation method and application thereof |
| TWI838039B (en) | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
| WO2013055958A1 (en) * | 2011-10-11 | 2013-04-18 | Genentech, Inc. | Improved assembly of bispecific antibodies |
| AU2012328322A1 (en) * | 2011-10-27 | 2014-06-12 | Genmab A/S | Production of heterodimeric proteins |
| EP2831089A1 (en) * | 2012-03-30 | 2015-02-04 | Krishnan, Archana Rajesh | Process for renaturation of polypeptides |
-
2015
- 2015-03-25 US US14/668,820 patent/US10647777B2/en active Active
- 2015-05-26 TW TW108146840A patent/TWI736071B/en active
- 2015-05-26 TW TW104116743A patent/TWI707693B/en active
- 2015-05-28 JP JP2016569829A patent/JP6742919B2/en active Active
- 2015-05-28 CA CA2950190A patent/CA2950190C/en active Active
- 2015-05-28 CN CN201580041180.0A patent/CN107001407B/en active Active
- 2015-05-28 WO PCT/US2015/033048 patent/WO2015184183A1/en active Application Filing
- 2015-05-28 KR KR1020167035608A patent/KR102457995B1/en active IP Right Grant
- 2015-05-28 AU AU2015266860A patent/AU2015266860B2/en active Active
- 2015-05-28 SG SG11201609480UA patent/SG11201609480UA/en unknown
- 2015-05-28 EP EP15728997.6A patent/EP3149033B1/en active Active
- 2015-05-28 RU RU2020115514A patent/RU2020115514A/en unknown
- 2015-05-28 SG SG10201810634UA patent/SG10201810634UA/en unknown
- 2015-05-28 RU RU2016151320A patent/RU2721592C2/en active
- 2015-05-28 MX MX2016015615A patent/MX2016015615A/en unknown
-
2016
- 2016-11-23 IL IL249142A patent/IL249142B/en unknown
-
2020
- 2020-04-08 US US16/842,864 patent/US20200299402A1/en active Pending
- 2020-04-30 JP JP2020079970A patent/JP7138135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI707693B (en) | 2020-10-21 |
| IL249142B (en) | 2022-02-01 |
| EP3149033A1 (en) | 2017-04-05 |
| US10647777B2 (en) | 2020-05-12 |
| IL249142A0 (en) | 2017-01-31 |
| RU2020115514A (en) | 2020-11-30 |
| CN107001407B (en) | 2021-10-15 |
| KR20170007457A (en) | 2017-01-18 |
| RU2016151320A3 (en) | 2019-01-25 |
| AU2015266860B2 (en) | 2021-01-28 |
| CA2950190A1 (en) | 2015-12-03 |
| CN107001407A (en) | 2017-08-01 |
| KR102457995B1 (en) | 2022-10-24 |
| WO2015184183A1 (en) | 2015-12-03 |
| JP2020124215A (en) | 2020-08-20 |
| US20160108127A1 (en) | 2016-04-21 |
| JP6742919B2 (en) | 2020-08-19 |
| RU2721592C2 (en) | 2020-05-20 |
| MX2016015615A (en) | 2017-04-25 |
| AU2015266860A1 (en) | 2016-12-15 |
| EP3149033B1 (en) | 2023-07-26 |
| TWI736071B (en) | 2021-08-11 |
| RU2016151320A (en) | 2018-06-28 |
| CA2950190C (en) | 2023-01-17 |
| TW201609134A (en) | 2016-03-16 |
| JP7138135B2 (en) | 2022-09-15 |
| TW202031290A (en) | 2020-09-01 |
| SG11201609480UA (en) | 2016-12-29 |
| US20200299402A1 (en) | 2020-09-24 |
| JP2017518293A (en) | 2017-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002900A (en) | Treating lymphomas. | |
| MX2018016258A (en) | Improved differentiation method. | |
| MA40459A (en) | Anti-age antibodies for treating inflammation and auto-immune disorders | |
| EA202091598A2 (en) | THE PROCESS OF CONTROL OF THE CONTENT OF GLYCANS IN THE COMPOSITION | |
| MY186864A (en) | Fusion immunomodulatory proteins and methods for making same | |
| MX2016016617A (en) | Treating myelomas. | |
| MX2016016886A (en) | Anti-axl antibodies. | |
| MX2017007941A (en) | Anti-axl antagonistic antibodies. | |
| EA201891709A1 (en) | ANTIGENSBINKING PROTEINS, BINDING PD-L1 | |
| SG10201810634UA (en) | Controlling the formation of disulfide bonds in protein solutions by adding reducing agents | |
| MX2024008826A (en) | Composition for controlled ovarian stimulation. | |
| MX359794B (en) | Anti-hepcidin antibodies and uses thereof. | |
| WO2014008480A3 (en) | Cell line expressing single chain factor viii polypeptides and uses thereof | |
| MX2016005205A (en) | Cmp-containing, high protein denatured whey protein compositions, products containing them, and uses thereof. | |
| MX2018001536A (en) | Method for the reduction of host cell proteins in affinity chromatography. | |
| MX2022008800A (en) | Control systems and methods suitable for use with power production systems and methods. | |
| PH12016500158A1 (en) | Methods for controlling fucosylation levels in proteins | |
| SG10201907901XA (en) | Antibodies, uses & methods | |
| MX2015014424A (en) | Mitochondrial proteins constructs and uses thereof. | |
| MX2016004802A (en) | Anti-rsp02 and/or anti-rsp03 antibodies and their uses. | |
| GB2533756A (en) | Flexible role-based authorization model | |
| EA202190244A3 (en) | OVEREXPRESSION OF N-GLYCOSYLATION PATH REGULATORS FOR MODULATION OF GLYCOSYLATION OF RECOMBINANT PROTEINS | |
| MX2015010023A (en) | Anti-cd83 antibodies and use thereof. | |
| EA201790360A1 (en) | GETTING THE COMPLETELY PROCESSED AND FUNCTIONAL FACTOR X IN THE FURINE-SECRETING SYSTEM OF MAMMALIC EXPRESSION | |
| GB2546911A (en) | Pivot block |